Compare Adaptive Biotechnologies Corp (ADPT) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dollar Tree, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Dollar Tree, Inc. trades at $123.81 (market cap $23.57B). The key difference: Dollar Tree, Inc. is far larger — about 7.1× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | DLTR | |
|---|---|---|
Market Cap | $3.33B | $23.57B |
Sector | Health | Health |
52-Week High | $22.37 | $141.21 |
52-Week Low | $10.24 | $85.04 |
Enterprise Value | $3.19B | $30.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Dollar Tree (DLTR) trades at $122.65, down 1.13% on the day, but maintains a bullish technical signal with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights a new $2.5 billion share repurchase authorization, signaling management confidence. Revenue for 2025 was $17.58 billion, though net income was impacted by a significant tax expense, resulting in a loss. Analyst consensus is bullish with a $130.70 price target, and institutional sentiment is positive amid evolving value retail strategies.
The outlook for DLTR is cautiously optimistic, driven by earnings momentum, share buybacks, and margin improvements. Key opportunities include multi-price strategy gains and cost controls, but risks involve traffic softness, inflationary pressures, and competitive threats. The stock's current valuation metrics, such as a P/E of 19.5, appear reasonable relative to growth prospects, though investors should monitor execution against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
